key: cord-1012048-cu3sgq5z
authors: Jaworski, Juan P.
title: Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
date: 2020-11-25
journal: Biomed J
DOI: 10.1016/j.bj.2020.11.011
sha: d647f3ccdd927d4d4d082779ec837b330bf483bd
doc_id: 1012048
cord_uid: cu3sgq5z

The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises. Several vaccine approaches and repurposed drugs are currently under evaluation for safety and efficacy. However, none of them have been approved for COVID-19 yet. Meanwhile, several nMAbs targeting SARS-CoV-2 spike glycoprotein are in different stages of development and clinical testing. Preclinical studies have shown that cocktails of potent nMAbs targeting the receptor binding site of SARS-CoV-2, as well as broad-nMAbs targeting conserved regions within the virus spike, might be effective for the treatment and prophylaxis of COVID-19. Currently, several clinical trials have started to test safety, tolerability, PKs and efficacy of these nMAbs. One paramount limitation for the use of nMAbs in clinical settings is the production of large amounts of MAbs and the high costs related to it. Cooperation among public and private institutions coupled with speed of development, rapid safety evaluation and efficacy, and early planning for scale-up and manufacture will be critical for the control of COVID-19 pandemic.

from an acute excessive virus replication followed by an uncontrolled inflammation and an exacerbated immunity, explaining why in 32 some patients, disease severity increases when viral load decreases [16, 17] .

SARS2 is a large enveloped RNA virus, containing a single-stranded, positive-sense RNA genome that encodes for a series of 34 structural and non-structural proteins, as well as a group of accessory genes. The envelope spike (S) protein of CoVs is a trimeric type-35 1 integral membrane protein and class-1 fusion protein which possess 3 copies of an N-terminal subunit (S1) that mediates receptor 36 attachment and 3 copies of a C-terminal subunit (S2) that mediates virus-cell membrane fusion. The S1 subunit contains 4 domains 

SARS2 spike glycoprotein is the main target of neutralizing antibodies (NAbs) and several neutralizing monoclonal antibodies (nMAbs) targeting different epitopes within the virus spike have been recently described. Moreover, several preclinical studies have 48 demonstrated that SARS2 nMAbs can suppress virus replication and disease severity in different animal models. In the absence of an 49 effective treatment for COVID-19, passive immunization with nMAbs has recently gained interest as a therapeutic approach to reduce In COVID-19 patients, viral load peak occurs concomitantly or shortly after symptoms onset. After peaking, viral load decreases 62 slowly and is detectable for up to 4 weeks [22, 23] . However, infective virus has been isolated from the upper respiratory tract only 63 within the first week after symptom onset [22] . As the virus replicates, the adaptive immunity is stimulated to generate cellular 64 responses and antibodies (Abs), including NAbs in the majority of SARS2 infected symptomatic individuals [24] . IgM, IgG and IgA antibodies directed to SARS2 external S and internal N proteins develop within the first week after symptoms onset and peak two 66 weeks after symptoms onset [22, 23] . In 50% of individuals, seroconversion occurs one week after symptoms onset and 100% of 67 individuals seroconvert by the end of the second week after symptom development [22, [25] [26] [27] [28] . Several studies reported an inverse 68 correlation between viral loads and SARS2 specific-Abs; however, by the time that Abs develop, viral loads have already started to 69 decrease indicating that innate and/or cellular adaptive immunity contribute to the initial virus containment [22, 23, 25] . Additionally, 70 the Ab response can be weak or absent in asymptomatic or mild infections, suggesting at least a partial control of the virus by innate 71 or T-cell mediated immunity [29, 30] . Paradoxically, several studies have found a positive correlation between specific-Ab titers and 72 disease severity, suggesting that a robust Ab response alone is insufficient to avoid severe disease and point out that the timing of Ab 73 development might be crucial for efficient virus control [25, 27, 28, 31, 32] . The one-week gap between peak viral load and 74 seroconversion suggests that the Ab response fails to efficiently control virus load during the first two weeks of infection and 75 consequently, the excessive virus replication within this period could ignite the inflammatory process associated with severe disease.

In addition, a larger antigenic exposure associated with virus replication might provoke the development of higher titers of antibodies 77 in severe disease outcomes. Alternatively, it has been proposed that antibody dependent enhancement (ADE), a mechanism triggered 78 by specific Abs, could potentially increase disease severity. ADE has been described for other viruses such as dengue virus (DENV) 79 and respiratory syncytial virus (RSV) [33] [34] [35] . Although, ADE has also been described for SARS1 in vitro and in animal models,

there is no evidence that this might happen in SARS2 infection in humans [36] .

patients had large reduction in viral loads and most were virus negative 3 days after infusion [45, 46] . cross-react with SARS2 [21]. In a similar fashion, the plasma from COVID-19 convalescent patients cross-react with SARS1, and to a 95 lesser extent with MERS and common cold CoVs [47] . Although the reactivity of COVID-19 plasmas against endemic CoVs has been 96 associated with previous encounter to such type of viruses, its reactivity against MERS and SARS1 has proven to be due to cross-97 reactivity against conserved epitopes within S protein [47] . COVID-19 patients develop anti-S1 and anti-RBD antibodies; however, 98 antibodies that effectively disrupt the binding of S protein and ACE2 receptor account for a small fraction of them 99 [30, 37, 38, 42, 43, 48, 49] . 

Several monoclonal antibodies (MAbs) targeting the RBS of SARS1 have been described (i.e., CR3014, M396 and S230). Although 106 these MAbs effectively neutralize SARS1 most of them do not cross neutralize SARS2, due to differences in the primary amino acid 107 sequence of RBS among these viruses. However, these observations supported the discovery and characterization of SARS2 MAbs 108 from COVID-19 patients. Over the past two decades, different programs from several institutions (i.e., NIAID Center for HIV/AIDS reactivity could occur within S protein but outside ACE2-binding site [37] .

continuous patch in the surface of the RBD [56]. This highly conserved area which spans from ACE2-binding site to the epitope 144 recognized by MAb CR3022 explains cross-reactivity found in these set of antibodies. In addition, Wrapp and colleagues isolated 145 SARS-VHH-72, a single chain antibody from a llama immunized with prefusion-stabilized SARS1 spike that cross reacted with 146 SARS2 [57] . SARS VHH-72 prevents the binding of ACE2 through a partially overlapping epitope of MAb CR3022. When two 147 copies of this VHH were coupled as a bi-valent IgG-Fc fusion (named VHH72-Fc) the construct was also able to neutralize SARS2. might have a strong negative impact in viral fitness. For that reason, Abs targeting this particular site of neutralization might be more colleagues isolated potent and diverse nMAbs targeting several epitopes on SARS2 spike [65] . Apart from those antibodies directed to 154 the RBD and NTD, the author described two nMAbs targeting novel quaternary epitopes located on top of SARS2 spike.

Expanding the number of potent nMAbs with different specificities against S protein will allow the formulation of more effective 156 nMAb cocktails; such combination of nMAbs accounting for different specificities may provide a powerful way to minimize 157 mutational escape by SARS2 [62] . Moreover, the rational development of nMAb cocktails targeting different sites of vulnerability 158 within the S protein could confer a synergistic neutralizing effect. Anti-SARS2 nMAbs described in Table 1 have been characterized 159 in detail by in vitro binding affinity, epitope mapping by competition assays, target specificity by cryo-EM and most importantly, for 160 in vitro and in vivo neutralization, using different platforms. Remarkably, these antibodies have proven to be effective preventing 161 infection of target cells, and most importantly blunting virus replication and pathogenicity in different animal models (i.e. hu-ACE2 162 transgenic mice, Syrian golden hamster and non-human primates (NHPs) [38, 42, 43, 49, 64, 66] . Overall, these studies indicate that 163 several nMAbs have the potential to be used either prophylactically or therapeutically to avoid and/or control SARS2 infection. 

IgG contains two antigen combining sites (Fabs) and an Fc region that interacts with various Fc receptors (FcRs) on immune cells.

MAbs differ from antiviral drugs in that in addition to potent viral particle neutralization and high specificity they can engage the host 168 immune cells (i.e., NK, neutrophils and macrophages) through their FcRs and trigger several immune effector mechanisms (i.e., 169 antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular viral inhibition); 170 furthermore, MAbs can induce complement-dependent cytotoxicity through their Fc domain [67] . Altogether, these effector functions nMAbs over CP treatment [75] . The finding that ansuvimab (MAb114) is safe and effective reducing the mortality rate of Ebola virus 197 disease from 67% to 34%, underscore the potential use of MAb therapy during a deadly infectious disease outbreak [75] [76] [77] . For HIV- 

In addition, it has not been reported that CoVs produce persistent infection and no within-host viral reservoir has been described for the MAb levels in respiratory mucosa, where it might confer higher protection against SARS2 infection. ratio; moreover, regulatory approval rates for MAbs are about 20% compared with 5% for new chemical entities [99] . However, Table 1 ). In addition, Sinocelltech LTD (Beijing, CN) is enrolling 33 participants into a phase 1 clinical 308 trial for nMAb SCTA01/H014 (NCT04483375) ( Table 1) . Furthermore, TYCHAN (SG) started a phase 1 clinical trial to test TY027 hospitalized COVID-19 patients. It is anticipated that several other anti-SARS2 nMAbs will resume clinical trials in the short future.

Finally, Celltrion Healthcare (KR) announced they will start a phase 1 clinical trial to test nMAb CT-P59. 

The SARS2 pandemic has caused unprecedented global health and economic damages, and the situation is not under control yet.

National Health Services worldwide, including those from the most developed countries were overwhelmed due to a high amount of 318 severe ill patients in a reduced time-frame, and thousands of lives were lost due to unpreparedness and controversial political 319 decisions. Although several vaccine candidates and repurposed drugs are currently being evaluated for safety and efficacy in record 320 time, none of them have been approved for COVID-19 use. Experts in the field agree that a vaccine will not be available in the short 321 future; once such vaccine become available, universal accessibility has to be granted. Additionally, some populations might not 322 respond well to it (i.e., the elderly or immunocompromised).

Several nMAbs targeting different epitopes on SARS2 spike protein are being tested for the prevention and treatment of COVID-19.

The combination of potent-nMAbs targeting the RBS and broad-nMAbs targeting conserved regions within the spike protein of 

Epidemiology and cause of severe acute respiratory syndrome (SARS)

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV

Quantifying SARS-CoV-2 transmission suggests

Johns Hopkins Coronavirus Resource Center. COVID-19 Map -Johns Hopkins Coronavirus Resource Center. Johns Hopkins 453 COVID-19 Res Cent

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

A novel coronavirus outbreak of global health concern

Epidemiological and clinical characteristics of 99 cases of

Antibody responses to SARS-CoV-2 in patients of novel coronavirus 483 disease 2019

Antibody responses to SARS-CoV-2 in patients with 485 COVID-19

Severe Acute Respiratory Syndrome 487

Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Isolation of potent SARS-CoV-2 neutralizing antibodies and

DNA vaccine protection against SARS-CoV-513 2 in rhesus macaques. Science (80-) 2020:eabc6284

SARS-CoV-2 infection protects against 515 rechallenge in rhesus macaques. Science (80-) 2020:eabc4776

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus 517 macaques. Science (80-) 2020:eabc5343

A noncompeting pair of human neutralizing antibodies block COVID-519 19 virus binding to its receptor ACE2

A human neutralizing antibody targets the receptor-binding site of

The Effectiveness of Convalescent

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High

Pandemic Preparedness: Developing Vaccines and

A neutralizing human antibody binds to the N-terminal domain of

Neutralization of SARS-CoV-2 by Destruction of the

A human monoclonal antibody blocking

Cross-neutralization of SARS-CoV-2 by a 550 human monoclonal SARS-CoV antibody

Broad neutralization of SARS-related viruses

Structural Basis for Potent Neutralization 554 of Betacoronaviruses by Single-Domain Camelid Antibodies

Antibody cocktail to SARS-CoV-2 spike protein prevents

A highly conserved cryptic epitope in the receptor binding domains

REGN-COV2 antibodies prevent and treat SARS-CoV-2

The role of Fc-FcγR interactions in IgG-mediated microbial neutralization

Complexes in the Enhancement of Endogenous Antiviral Immunity by Short Passive Immunotherapy

Prospects for engineering HIV-specific antibodies for enhanced effector function and 584 half-life

Fc receptor but not complement binding 586 is important in antibody protection against HIV

SARS-CoV-2 Vaccines: Status Report

Convalescent serum lines up as first-choice treatment for coronavirus

COVID-19 Research in Brief

The convalescent sera option for containing COVID-19

Protective monotherapy against lethal Ebola virus

Rational Design of Envelope Identifies Broadly 603 Neutralizing Human Monoclonal Antibodies to HIV-1

Identification of a CD4-Binding-Site Antibody to HIV that

Broad and Potent Neutralizing Antibodies from 608 an African Donor Reveal a New HIV-1 Vaccine Target

Broad neutralization coverage of HIV by multiple 611 highly potent antibodies

Sequence and Structural Convergence of Broad 613 and Potent HIV Antibodies That Mimic CD4 Binding

Virologic effects of broadly neutralizing antibody 616 VRC01 administration during chronic HIV-1 infection

Viraemia suppressed in HIV-1-infected humans by

HIV-1 antibody 3BNC117 suppresses viral 621 rebound in humans during treatment interruption

Antibody 10-1074 suppresses viremia in HIV-1-623 infected individuals

Effect of HIV Antibody VRC01 on Viral

Combination therapy with anti-HIV-1 antibodies

Updated Guidance for Palivizumab

Basis and Statistical Design of the Passive HIV-632

Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Passive transfer of modest titers of potent 635 and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

A mouse model for HIV-1 entry

Use of broadly neutralizing antibodies for HIV-1 prevention

Safety, pharmacokinetics, and immunological 642 activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-643 uninfected adults: Results of a phase 1 randomized trial

Enhanced antibody half-life improves in 646 vivo activity

Reproducing SIVΔnef vaccine correlates of

Enhanced neonatal Fc receptor function improves 650 protection against primate SHIV infection

Single-Dose Nirsevimab for Prevention of

Monoclonal antibody successes in the clinic

Safety and antiviral activity of combination HIV-1 658 broadly neutralizing antibodies in viremic individuals

The author thanks Lucas Matias Ferreri and Thiago Carvalho for reviewing this manuscript and their helpful comments 425 426 427